Daré Bioscience, Inc. / Fundamentals

    Income statement

    Net revenue
    -€15.27K
    Cost of goods sold
    €274.12K
    Gross profit
    -€12.28M
    SG&A expenses
    €7.53M
    R&D expenses
    €8.36M
    EBITDA
    -€15.39M
    D&A
    €547.14K
    EBIT
    -€15.94M
    Interest expenses
    €231.63K
    EBT
    -€16.05M
    Tax expenses
    €0.00
    Net income
    -€16.05M

    Cash flow statement

    Net deferred tax
    €0.00
    Non-cash items
    €621.75K
    Changes in working capital
    €4.83M
    Operating cash flow
    -€9.99M
    Capex
    €245.37K
    Other investing cash flow
    €0.00
    Net investing cash flow
    -€245.37K
    Total cash dividends paid
    €0.00
    Issuance of common stock
    €833.91K
    Debt repayment
    -€234.30K
    Other financing cash flow
    -€162.08K
    Net financing cash flow
    €437.52K
    Foreign exchange effects
    -€58.49M
    Net change in cash
    -€9.82M
    Cash at end of period
    €4.60M
    Free cash flow
    -€9.75M

    Balance sheet

    Cash and cash equivalents
    €4.34M
    Cash and short-term investments
    €4.34M
    Total receivables
    €162.27K
    Inventory
    €0.00
    Other current assets
    €1.19M
    Total current assets
    €5.70M
    Property, plant & equipment
    €4.58M
    Goodwill
    €0.00
    Intangible assets
    €0.00
    Long-term investments
    €258.78K
    Other non-current assets
    €664.11K
    Total non-current assets
    €5.50M
    Total assets
    €11.20M
    Accounts payable
    €1.52M
    Short-term debt
    €2.09M
    Other current liabilities
    €2.34M
    Total current liabilities
    €16.58M
    Long-term debt
    €4.74M
    Deferred tax liabilities
    €0.00
    Other non-current liabilities
    €0.00
    Total non-current liabilities
    €5.60M
    Total liabilities
    €22.18M
    Common stock
    €778.92
    Retained earnings
    -€158.44M
    Other equity
    -€347.47K
    Total equity
    -€10.98M
    Total liabilities and shareholders' equity
    €11.20M

    Company information

    Market capitalization
    €17.85M
    Employees
    21
    Enterprise Value
    €22.01M

    Company ratios

    Gross margin
    80,447.7% Much worse than peer group: 1,391,110,192,041,724,200.0%
    EBITDA margin
    100,812.0% Much worse than peer group: 19,659,601,233,196,554,000.0%
    EBIT margin
    104,388.5% Much worse than peer group: 15,272,788,036,768,966,000.0%
    EBT margin
    105,098.5% Much worse than peer group: 20,234,527,297,531,674,000.0%
    Net margin
    105,098.5% Much worse than peer group: 24,001,316,297,766,704,000.0%
    ROE
    146.1% Much better than peer group: -148.3%
    ROA
    -143.3% Much worse than peer group: -114.1%
    Asset turnover
    -0.1% Worse than peer group: 12.4%
    FCF margin
    67,058.0% Much worse than peer group: 19,263,620,372,692,830,000.0%
    FCF yield
    -57.4%
    Efficiency ratio
    -100,712.0%
    Net sales per employee
    -€727.08
    Net income per employee
    -€764.15K

    Notifications